MedTrace Logo

A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease

NCT07450144 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-23

No results posted yet for this study

Summary

The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease. Specific objectives include:

1. To assess how many MetALD patients accept the invitation to participate in the trial
2. To assess the retention rate of the participants through 3 and 6 months after treatment initiation
3. To assess the acceptability of the LLM-based chatbot in terms of participants' compliance and usability rating
4. To estimate the intervention effect on alcohol reduction
5. To explore the participants' perception and experiences in the chatbot

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Metabolic Alcohol-Related Liver Disease

Interventions

BEHAVIORAL

LLM-based chatbot

Over the three months following randomisation, an LLM-based chatbot will interact with each participant individually to deliver four personalized sessions of alcohol reduction information and advice, and participants will also be allowed to contact the chatbot at any time.

BEHAVIORAL

Telephone counseling

Over the three months following randomisation, a trained counsellor will conduct four individual daytime telephone sessions with each participant to provide personalised information and advice on reducing alcohol consumption.

BEHAVIORAL

Alcohol Brief Intervention

Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-18
Primary Completion
2027-05-22
Completion
2027-07-22

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07450144 on ClinicalTrials.gov